By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Catabasis Pharmaceuticals, Inc. 

161 First Street
Suite 1A
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-349-1971 Fax: 617-273-2637


SEARCH JOBS


Industry
Pharmaceutical






Company News
Catabasis (CATB) Announces Pricing Of $10 Million Offering Of Common Stock 9/23/2016 9:27:54 AM
Catabasis (CATB) Reports Second Quarter 2016 Financial Results And Recent Corporate Highlights 8/12/2016 8:48:57 AM
Catabasis (CATB) To Present At 2016 Wedbush PacGrow Healthcare Conference 8/9/2016 11:12:46 AM
4 Biotech Stocks That Could Triple In Value This Year 8/4/2016 6:37:42 AM
Catabasis (CATB) To Report Second Quarter 2016 Financial Results And Recent Corporate Developments On Thursday, August 11 7/28/2016 11:20:43 AM
Catabasis (CATB) Names Joseph Johnston VP, Regulatory Affairs 7/12/2016 10:36:25 AM
Catabasis (CATB) Announces The Initiation Of An Open-Label Extension For The Movedmd Trial Studying Edasalonexent (CAT-1004) In Duchenne Muscular Dystrophy 7/7/2016 10:59:12 AM
Catabasis (CATB)To Present Edasalonexent (CAT-1004), An Oral Agent Targeting NF-Kb: Movedmdsm Trial In Duchenne Muscular Dystrophy (DMD) At The 2016 PPMD Annual Connect Conference 6/20/2016 10:18:03 AM
Catabasis (CATB) To Present Edasalonexent (CAT-1004), An Oral Agent Targeting NF-Kb: Movedmd Trial In Duchenne Muscular Dystrophy (DMD) At The 2016 PPMD Annual Connect Conference 6/20/2016 9:35:46 AM
CureDuchenne And Catabasis (CATB) To Host A Webinar To Review Information On Edasalonexent (CAT-1004) And The MoveDMD Trial On June 22, 2016 6/14/2016 8:22:44 AM
12345678910
//-->